OUR DEVELOPMENT PORTFOLIO
latest update 21 January 2019
Cardiovascular diseases
Diabetes
Cancer
Immune-
Inflammatory diseases
Neuropsychiatric diseases
Phase 1
|
Ischemic stroke TAFIa inhibitor |
|
|
Chronic heart failure Anti Mir92a |
|
Cancer Mcl1 inhibitor |
|
|
Cancer Bcl2 inhibitor |
|
|
Cancer UCART 19 |
|
|
Cancer Flotetuzumab (CD123xCD3) |
|
|
Cancer MPS1 inhibitor |
|
|
Colorectal cancer, 2nd line Trifluridine/Tipiracil |
|
|
Lung cancer, 2nd line Liposomal Irinotecan |
|
|
Cancer, 1st line mPaCa / Liposomal Irinotecan |
Phase 2
|
|
Venous leg ulcers |
|
Osteoarthritis ADAMTS-5 inhibitor |
|
Post stroke GABA A α5 antagonist |
Phase 3
|
|
Chronic heart failure Omecamtiv mecarbil |
|
Type 2 diabetes Exenatide implant |
|
|
Lymphoma, 2nd line Pixantrone |
|
|
Colorectal cancer, 1st line Trifluridine/Tipiracil |
|
|
Autism Bumetanide |